Why in news The European Medicines Agency (EMA) is reviewing Valneva’s chikungunya vaccine after serious side effects in older adults. T...
Why in news
The European Medicines Agency (EMA) is reviewing Valneva’s chikungunya vaccine after serious side effects in older adults.
The vaccine, Ixchiq, has been temporarily suspended for adults aged 65 and older.
17 serious adverse events, including 2 deaths, have been reported in people aged 62 to 89.
The exact cause and connection between the side effects and the vaccine are still unclear.
Valneva is continuing to monitor the situation and cooperate with health authorities.
COMMENTS